Business
Telix Bets Up to $2.35B on ITM to Build a Radiopharmaceutical Powerhouse
The deal pairs Telix’s targeted cancer therapies with ITM’s ability to make the scarce radioactive isotopes the whole field depends on — a bid to own more of a fast-growing, supply-constrained business.